PCM
GSK icon

Prelude Capital Management’s GSK GSK Stock Holding History

Prelude Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30,391
Closed -$1.07M – 1302
2022
Q4 		$1.07M Buy
+30,391
New +$1.01M 0.06% 358
2017
Q4 		– Sell
-834
Closed -$42K – 1485
2017
Q3 		$42K Sell
834
-18,860
-96% -$957K ﹤0.01% 1149
2017
Q2 		$1.06M Sell
19,694
-14,560
-43% -$776K 0.1% 206
2017
Q1 		$1.8M Buy
+34,254
New +$1.74M 0.17% 145

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's GSK Position: Q1 2023 in Review

Prelude Capital Management sold out of GSK (GSK) in Q1 2023, closing a stake of 30,391 shares — an estimated $1.07M sold.

Prelude Capital Management first reported a position in GSK in Q1 2017 and held it in 4 quarters. The position peaked at $1.8M in Q1 2017. 809 funds tracked by Wall St. Rank hold GSK as of Q1 2023.

  • Prelude Capital Management reported no remaining GSK position as of Q1 2023 after selling out during the quarter.
  • Prelude Capital Management sold 30,391 GSK shares in Q1 2023, an estimated $1.07M.
  • Prelude Capital Management first reported a position in GSK in Q1 2017 and held it in 4 quarters.
  • Prelude Capital Management's GSK position peaked at $1.8M in Q1 2017.
  • 809 funds tracked by Wall St. Rank held GSK as of Q1 2023.

Based on Prelude Capital Management's 13F filing for Q1 2023, filed 15 May 2023.